WA
LGND icon

Westfuller Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Westfuller Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.66K Sell
13
-3
-19% -$594 ﹤0.01% 608
2025
Q4 		$3.02K Hold
16
– – ﹤0.01% 617
2025
Q3 		$2.83K Buy
+16
New +$2.38K ﹤0.01% 599

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Westfuller Advisors's LGND Position: Q1 2026 in Review

Westfuller Advisors reduced its Ligand Pharmaceuticals (LGND) stake by 19% in Q1 2026, selling an estimated $594 and leaving 13 shares worth $2.66K. The position accounts for ﹤0.01% of the portfolio, ranked #608.

Westfuller Advisors first reported a position in LGND in Q3 2025 and has held it in 3 quarters since. The position peaked at $3.02K in Q4 2025. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Westfuller Advisors held 13 shares of Ligand Pharmaceuticals worth $2.66K as of Q1 2026.
  • Westfuller Advisors sold 3 Ligand Pharmaceuticals shares in Q1 2026, an estimated $594.
  • Ligand Pharmaceuticals made up ﹤0.01% of Westfuller Advisors's portfolio in Q1 2026, its #608 holding.
  • Westfuller Advisors first reported a position in Ligand Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Westfuller Advisors's Ligand Pharmaceuticals position peaked at $3.02K in Q4 2025.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Westfuller Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.